Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

M7824

- PMLiVE

Merck KGaA and Caris enter oncology partnership worth over $1.4bn

The alliance is aimed at accelerating the development of ADCs for cancer patients

- PMLiVE

Merck KGaA and C4 Therapeutics enter protein degrader partnership worth $756m

The collaboration will utilise C4T’s TORPEDO platform to target and degrade disease-associated proteins

- PMLiVE

Merck gains rights to Inspirna’s colorectal cancer drug for $45m upfront

Ompenaclid is in phase 2 development to treat advanced or metastatic colorectal cancer

- PMLiVE

Merck gains rights to Abbisko’s pimicotinib in deal worth over $70m

The candidate is currently in late-stage development for tenosynovial giant cell tumour

- PMLiVE

New study finds dose of subcutaneous cladribine could predict MS relapse risk

The disease affects approximately 130,000 people in the UK and currently has no cure

- PMLiVE

Merck KGaA and Hengrui Pharmaceuticals announce oncology partnership worth over €1.4bn

The deal includes a next-generation PARP1 inhibitor and an antibody drug conjugate

- PMLiVE

AbbVie files patent infringement lawsuit against BeiGene’s blood cancer drug Brukinsa

The BTK inhibitor was approved in the US earlier this year and had its patent issued last week

- PMLiVE

Janssen and AbbVie’s Imbruvica combination recommended by NICE for leukaemia

Approximately 3,800 people in the UK are diagnosed with chronic lymphocytic leukaemia each year

- PMLiVE

Merck KGaA’s MS drug put on partial clinical hold by FDA

Laboratory results suggested there were two cases of drug-induced liver injury during the phase 3 studies

- PMLiVE

Merck KGaA and Mersana partner in potential $830m deal

The companies will work together to develop novel antibody-drug conjugates

- PMLiVE

Janssen’s Imbruvica shows promise in chronic lymphocytic leukaemia study

The data was shared during the 2022 American Society of Hematology Annual Meeting

- PMLiVE

AbbVie’s Imbruvica bags FDA approval for paediatric patients with chronic graft versus host disease

The decision marks the first approved treatment for children with the condition under 12 years

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links